ClinicalTrials.gg
CompletedNCT04066621CRO-SBTUpdated Aug 28, 2019

PHase IV Clinical Trial of Ceftriaxone Sodium and Sulbactam Sodium for Injection (CRO-SBT)

A Phase 4 interventional study of Ceftriaxone Sodium and Sulbactam Sodium for Injection in Respiratory Tract Infections and Urinary Tract Infections in Children, sponsored by Xiangbei Welman Pharmaceutical Co., Ltd. Completed. Open to participants aged 6 Years to 14 Years. Per ClinicalTrials.gov, last updated 2019-08-28.

Sponsored by Xiangbei Welman Pharmaceutical Co., Ltd · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 3 months after the study started (first participant enrolled Apr 2015, registered Aug 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
6 Years to 14 Years
Sex
All
01

Study summary

To evaluate the safety and efficacy of treatment of children with acute bacterial infection disease with Ceftriaxone Sodium and Sulbactam Sodium for Injection in the condition of widely used, and provide the basis of adjusting the dosage regimen for children in particular.

Read the detailed description

Ceftriaxone sodium and sulbactam sodium for injection (2:1)plays a therapeutic role by the former inhibiting bacterial cell wall synthesis,the latter making irreversible competitive inhibition of β-lactamase.The antimicrobial effect of Ceftriaxone can be enhanced by the two combined. The compound specifically aims to the mechanism of bacterial resistance, extending the life of Ceftriaxone in the treatment-resistant pathogen infections.

02

Conditions studied

  • Respiratory Tract Infections
  • Urinary Tract Infections in Children
03

In context

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.

This study's enrollment of 30 is below the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.

Browse Respiratory Tract Infections studies →

Lead sponsor

Xiangbei Welman Pharmaceutical Co., Ltd is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female children ages≥6 years to\< 14 years.
  • Weight≥18kg who in hospital or outpatients with good compliance;
  • The subjects were diagnosed as respiratory infection, urinary tract infection or other infection caused by the compound sensitive bacteria after clinical symptoms and signs laboratory examination and auxiliary examination according to the clinically recognized diagnostic criteria, and should be treated with systemic antibiotics;
  • Subjects had not used effective antimicrobial agents before screening, or had used antimicrobial agents but the efficacy was not obvious;
  • No severe liver and kidney cardiovascular and hematopoietic diseases were found in the subjects ( and ALT were not more than 1.5 times of the value,Cr was within the normal range);
  • Subject guardian and/or subject's own informed consent subject volunteers to participate in this study and has signed the subject's informed consent.

Exclusion criteria

Exclusion Criteria:

  • History of reactions to carbapenems, cephalosporins, penicillin, other β-lactam antibiotics;
  • Patients with specific infections who require treatment with other antimicrobial agents;
  • Use of penicillin roxithromycin vitamin B vitamin C and other drugs may interfere with the efficacy or safety evaluation of drugs at the same time;
  • Patients at risk of serious drug interactions due to combination of medications;
  • Patients who have other diseases and thought to affect efficacy evaluations or be poor compliance;
  • Attended clinical trial in three monthes.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    CRO-SBT

    Ceftriaxone Sodium and Sulbactam Sodium for Injection(2:1)

    Drug: Ceftriaxone Sodium and Sulbactam Sodium for Injection

Interventions

  • DrugCeftriaxone Sodium and Sulbactam Sodium for Injection

    Drug pages: Ceftriaxone · Sulbactam

    daily dose was 75 mg/kg by weight, 1-2 times ivgtt per day, 4 to 14 days

    Also known as: weipufen

06

What researchers measure

Primary outcomes

  1. The cure rate of patients

    Clinically effective/Clinically ineffective

    Time frame: Seven days after treatment

Secondary outcomes

  1. bacterial clearance rate

    end of treatment of bacteriological efficacy (bacterial clearance rate)

    Time frame: 48 hours after treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Jun 2016, 13 months.

Of 29 phase 4 interventional studies under Respiratory Tract Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 51. This study's 13 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2019
First posted
Aug 26, 2019
StartActual
Apr 28, 2015
Primary completionActual
Jun 11, 2016
CompletionActual
May 27, 2017
Last update
Aug 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04066621
Lead sponsor
Xiangbei Welman Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Aug 26, 2019
Start date
Apr 28, 2015
Primary completion
Jun 11, 2016
Completion
May 27, 2017
Last update
Aug 28, 2019

Study contacts

yuhua hu, Doctor
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ceftriaxone · Sulbactam

Start the discussion